Site-Specific N-Glycan-Resolved PK Assessment of Therapeutic Proteins Using Hybrid LBA-HRMS and LC-MS/MS
Understanding how glycosylation and its metabolic conversion shape the pharmacokinetics (PK) and pharmacodynamics (PD) of therapeutic proteins is essential for predicting exposure and efficacy. Lot-to-lot comparisons typically rely on aggregate PK metrics that obscure contributions from individual glycoforms, despite...